Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL584375 | 0.99 | CHRNB2 (0.33) | CYP1A2CYP19A1CYP2C9CYP2C19CHRNB2 | |
| SCHEMBL2360345 | 0.89 | CYP1A2 (0.32) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL588718 | 0.88 | CYP1A2 (0.33) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2327446 | 0.87 | CHRNB4 (0.30) | — | |
| SCHEMBL1854878 | 0.86 | PDE2A (0.37) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL584419 | 0.86 | CYP3A4 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL585273 | 0.86 | MAOA (0.34) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| Bromide SCHEMBL5014264 | 0.86 | — | — | |
| Dimethylamine SCHEMBL1861764 | 0.84 | KDM4E (0.38) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1856480 | 0.84 | FFAR1 (0.35) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | claimed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | claimed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| EP-2355816-A2 | NOVEL USES | Destiny Pharma Limited (GB) | 2011-08-17 | — | — | EP | claimed |
| WO-2010046663-A2 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2010-04-29 | — | — | WO | claimed |
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262511-A1 | Novel Uses | XDH, F12, ZFX | CYP1A2 505/4885CYP19A1 1115/4885CYP2C9 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.